Background Asparaginase (ASP) is a key component of pediatric acute lymphoblastic leukemia (ALL) therapy, but its use is limited by concerns about hypersensitivity, hepatic dysfunction, pancreatitis, thrombosis, and other toxicities. Here, ASPG is linked to pancreatitis.